Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3441-3450 Newer>

The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
The Motley Fool January 31, 2007 Brian Lawler	No Sickness for Amylin Sales of the drugmaker's type-2 diabetes drugs showed solid growth. Investors, take note.
Chemistry World February 2007 Derek Lowe	In the Pipeline Can the secret recipe for scientific breakthroughs be taught? And how much indigestion would that recipe cause in the pharmaceutical industry's boardrooms?
Chemistry World January 30, 2007 Bea Perks	BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool January 30, 2007 Brian Lawler	Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	Bristol-Myers Blames the Generic Again The fourth quarter's financial results are dominated by generic competition.
The Motley Fool January 29, 2007 Brian Lawler	ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
<Older 3441-3450 Newer> Return to current articles.